293 related articles for article (PubMed ID: 26453645)
1. No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
Munger KL; Fitzgerald KC; Freedman MS; Hartung HP; Miller DH; Montalbán X; Edan G; Barkhof F; Suarez G; Radue EW; Sandbrink R; Kappos L; Pohl C; Ascherio A
Neurology; 2015 Nov; 85(19):1694-701. PubMed ID: 26453645
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis.
Gieß RM; Pfuhl C; Behrens JR; Rasche L; Freitag E; Khalighy N; Otto C; Wuerfel J; Brandt AU; Hofmann J; Eberspächer B; Bellmann-Strobl J; Paul F; Ruprecht K
PLoS One; 2017; 12(4):e0175279. PubMed ID: 28388676
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.
Cortese M; Munger KL; Martínez-Lapiscina EH; Barro C; Edan G; Freedman MS; Hartung HP; Montalbán X; Foley FW; Penner IK; Hemmer B; Fox EJ; Schippling S; Wicklein EM; Kappos L; Kuhle J; Ascherio A;
Neurology; 2020 May; 94(18):e1950-e1960. PubMed ID: 32300060
[TBL] [Abstract][Full Text] [Related]
4. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2005 May; 293(20):2496-500. PubMed ID: 15914750
[TBL] [Abstract][Full Text] [Related]
5. Epstein-barr virus and multiple sclerosis risk in the finnish maternity cohort.
Munger KL; Hongell K; Cortese M; Åivo J; Soilu-Hänninen M; Surcel HM; Ascherio A
Ann Neurol; 2019 Sep; 86(3):436-442. PubMed ID: 31226219
[TBL] [Abstract][Full Text] [Related]
6. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis.
Lünemann JD; Tintoré M; Messmer B; Strowig T; Rovira A; Perkal H; Caballero E; Münz C; Montalban X; Comabella M
Ann Neurol; 2010 Feb; 67(2):159-69. PubMed ID: 20225269
[TBL] [Abstract][Full Text] [Related]
7. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.
Kuhle J; Disanto G; Dobson R; Adiutori R; Bianchi L; Topping J; Bestwick JP; Meier UC; Marta M; Dalla Costa G; Runia T; Evdoshenko E; Lazareva N; Thouvenot E; Iaffaldano P; Direnzo V; Khademi M; Piehl F; Comabella M; Sombekke M; Killestein J; Hegen H; Rauch S; D'Alfonso S; Alvarez-Cermeño JC; Kleinová P; Horáková D; Roesler R; Lauda F; Llufriu S; Avsar T; Uygunoglu U; Altintas A; Saip S; Menge T; Rajda C; Bergamaschi R; Moll N; Khalil M; Marignier R; Dujmovic I; Larsson H; Malmestrom C; Scarpini E; Fenoglio C; Wergeland S; Laroni A; Annibali V; Romano S; Martínez AD; Carra A; Salvetti M; Uccelli A; Torkildsen Ø; Myhr KM; Galimberti D; Rejdak K; Lycke J; Frederiksen JL; Drulovic J; Confavreux C; Brassat D; Enzinger C; Fuchs S; Bosca I; Pelletier J; Picard C; Colombo E; Franciotta D; Derfuss T; Lindberg R; Yaldizli Ö; Vécsei L; Kieseier BC; Hartung HP; Villoslada P; Siva A; Saiz A; Tumani H; Havrdová E; Villar LM; Leone M; Barizzone N; Deisenhammer F; Teunissen C; Montalban X; Tintoré M; Olsson T; Trojano M; Lehmann S; Castelnovo G; Lapin S; Hintzen R; Kappos L; Furlan R; Martinelli V; Comi G; Ramagopalan SV; Giovannoni G
Mult Scler; 2015 Jul; 21(8):1013-24. PubMed ID: 25680984
[TBL] [Abstract][Full Text] [Related]
8. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A
JAMA Neurol; 2015 Dec; 72(12):1458-65. PubMed ID: 26458124
[TBL] [Abstract][Full Text] [Related]
9. Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis.
Décard BF; von Ahsen N; Grunwald T; Streit F; Stroet A; Niggemeier P; Schottstedt V; Riggert J; Gold R; Chan A
J Neurol Neurosurg Psychiatry; 2012 Dec; 83(12):1170-3. PubMed ID: 22888143
[TBL] [Abstract][Full Text] [Related]
10. Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity.
Ingram G; Bugert JJ; Loveless S; Robertson NP
Eur J Neurol; 2010 Nov; 17(11):1386-9. PubMed ID: 20482607
[TBL] [Abstract][Full Text] [Related]
11. Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes.
Weinstock-Guttman B; Horakova D; Zivadinov R; Tamaño-Blanco M; Badgett D; Tyblova M; Vaneckova M; Seidl Z; Krasensky J; Bergsland N; Ramasamy DP; Hagemeier J; Havrdova E; Ramanathan M
J Neuroimmunol; 2013 Oct; 263(1-2):121-7. PubMed ID: 23916695
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples.
Salzer J; Nyström M; Hallmans G; Stenlund H; Wadell G; Sundström P
Mult Scler; 2013 Oct; 19(12):1587-91. PubMed ID: 23549431
[TBL] [Abstract][Full Text] [Related]
13. Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis.
Zivadinov R; Weinstock-Guttman B; Zorzon M; Uxa L; Serafin M; Bosco A; Bratina A; Maggiore C; Grop A; Tommasi MA; Srinivasaraghavan B; Ramanathan M
J Neuroimmunol; 2009 Apr; 209(1-2):123-30. PubMed ID: 19232441
[TBL] [Abstract][Full Text] [Related]
14. Multiple sclerosis and Epstein-Barr virus.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2003 Mar; 289(12):1533-6. PubMed ID: 12672770
[TBL] [Abstract][Full Text] [Related]
15. Conversion of clinically isolated syndrome to multiple sclerosis: a prospective study.
Kolčava J; Kočica J; Hulová M; Dušek L; Horáková M; Keřkovský M; Stulík J; Dostál M; Kuhn M; Vlčková E; Bednařík J; Benešová Y
Mult Scler Relat Disord; 2020 Sep; 44():102262. PubMed ID: 32570179
[TBL] [Abstract][Full Text] [Related]
16. Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression.
Tao C; Simpson-Yap S; Taylor B; Blizzard L; Lucas R; Ponsonby AL; Broadley S; van der Mei I;
Mult Scler Relat Disord; 2022 Mar; 59():103561. PubMed ID: 35131728
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D as an early predictor of multiple sclerosis activity and progression.
Ascherio A; Munger KL; White R; Köchert K; Simon KC; Polman CH; Freedman MS; Hartung HP; Miller DH; Montalbán X; Edan G; Barkhof F; Pleimes D; Radü EW; Sandbrink R; Kappos L; Pohl C
JAMA Neurol; 2014 Mar; 71(3):306-14. PubMed ID: 24445558
[TBL] [Abstract][Full Text] [Related]
18. Intrathecal EBV antibodies are part of the polyspecific immune response in multiple sclerosis.
Otto C; Oltmann A; Stein A; Frenzel K; Schroeter J; Habbel P; Gärtner B; Hofmann J; Ruprecht K
Neurology; 2011 Apr; 76(15):1316-21. PubMed ID: 21482946
[TBL] [Abstract][Full Text] [Related]
19. Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study.
Horakova D; Zivadinov R; Weinstock-Guttman B; Havrdova E; Qu J; Tamaño-Blanco M; Badgett D; Tyblova M; Bergsland N; Hussein S; Willis L; Krasensky J; Vaneckova M; Seidl Z; Lelkova P; Dwyer MG; Zhang M; Yu H; Duan X; Kalincik T; Ramanathan M
PLoS One; 2013; 8(1):e53996. PubMed ID: 23320113
[TBL] [Abstract][Full Text] [Related]
20. Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis.
Wesnes K; Myhr KM; Riise T; Kvistad SS; Torkildsen Ø; Wergeland S; Holmøy T; Midgard R; Bru A; Edland A; Eikeland R; Gosal S; Harbo HF; Kleveland G; Sørenes YS; Øksendal N; Bjørnevik K
Mult Scler Relat Disord; 2021 May; 50():102801. PubMed ID: 33636616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
